ALGN:NSD-Align Technology Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 207.11

Change

-3.90 (-1.85)%

Market Cap

USD 16.57B

Volume

0.96M

Avg Analyst Target

USD 413.71 (+99.75%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ALGN Stock Forecast & Price:
Based on the Align Technology Inc stock forecasts from 8 analysts, the average analyst target price for Align Technology Inc is USD 413.71 over the next 12 months. Align Technology Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Align Technology Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Align Technology Inc’s stock price was USD 207.11. Align Technology Inc’s stock price has changed by -6.89% over the past week, -16.04% over the past month and -68.88% over the last year.

About Align Technology Inc (ALGN:NSD)

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clea ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-1.56 (-1.90%)

USD32.46B 198.40 79.66
PODD Insulet Corporation

-1.78 (-0.77%)

USD16.39B 472.28 113.28
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD ABIOMED Inc

-3.30 (-1.33%)

USD11.46B 53.61 36.83
SWAV Shockwave Medical Inc

+2.23 (+0.81%)

USD9.83B 188.63 145.48
BRKR Bruker Corporation

+0.22 (+0.42%)

USD7.25B 27.18 15.48
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67
NARI Inari Medical Inc

-1.32 (-1.78%)

USD3.77B N/A -490.66
IRTC iRhythm Technologies Inc

-0.41 (-0.33%)

USD3.71B N/A -31.65
IART Integra LifeSciences Holdings

-1.13 (-2.60%)

USD3.53B 21.35 13.56

ETFs Containing ALGN

Symbol Name Weight Mer Price(Change) Market Cap
RPG Invesco S&P 500® Pure Gr.. 0.00 % 0.35 %

-1.52 (-1.04%)

USD2.37B
XRSM:F Xtrackers (IE) Public Lim.. 0.00 % 0.07 %

+0.04 (+0.11%)

USD0.11B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -68.49% 26% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.49% 26% F 19% F
Trailing 12 Months  
Capital Gain -68.72% 36% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.72% 36% F 24% F
Trailing 5 Years  
Capital Gain 11.19% 73% C 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.19% 73% C 58% F
Average Annual (5 Year Horizon)  
Capital Gain 28.13% 70% C- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.13% 70% C- 84% B
Risk Return Profile  
Volatility (Standard Deviation) 71.11% 35% F 18% F
Risk Adjusted Return 39.56% 80% B- 74% C
Market Capitalization 16.57B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.65 51% F 33% F
Price/Book Ratio 4.83 26% F 17% F
Price / Cash Flow Ratio 14.13 18% F 16% F
EV/EBITDA 16.84 13% F 13% F
Management Effectiveness  
Return on Equity 17.73% 94% A 85% B
Return on Invested Capital 21.47% 93% A 87% B+
Return on Assets 9.69% 95% A 93% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.20 54% F 44% F
Short Percent 2.81% 50% F 46% F
Beta 1.80 17% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.